As part of cost-cutting measures to support its lead program, Seres Therapeutics is laying off about 25% of its workforce, which includes people let go effective in August.Seres expects the cuts will help extend its cash runway into the second quarter of 2026.
All entries for: Oncology
September 19, 2025
Bristol Myers Squibb
Layoffs
Lawrenceville, NJ
10,001-50,000 employees
Bristol Myers Squibb is letting go of 282 employees in Lawrenceville, New Jersey, with effective dates in December 2025 and February and March of next year.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
September 18, 2025
X4 Pharmaceuticals
Layoffs
Boston, MA
51-200 employees
For the second time this year, X4 Pharmaceuticals is enacting a “strategic restructuring” initiative, in which it will let go of half of its employees in a bid to “sharpen operational focus and align resources” with its long-term strategy, These most recent staffing cuts are expected to affect some 50 employees. The strategic push will cost the company $3.3 million in one-time expenses for severance and other termination-related payments. Annualized savings are expected to hit $13 million, according to the SEC filing. X4 is also trimming its masthead. The biotech’s Board has terminated Chief Operating Officer Mary DiBiase, Chief Commercial Officer Mark Baldry and Chief Legal and Compliance Officer Natasha Thoren, all effective Sept. 15. A day later, Chief Medical Officer Christophe Arbet-Engels stepped down from his post.
Disease Area: Immune Diseases, Multiple, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
September 18, 2025
Innate Pharma
Layoffs
Rockville, MD
201-500 employees
Innate Pharma is laying off 30% of its workforce while putting its efforts and resources behind three of the company’s pipeline assets with the “highest potential” of delivering value both to patients and the biotech’s shareholders.
Disease Area: Immune Diseases, Oncology
Drug Type: Biologic
September 12, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck will terminate research and discovery efforts in the U.K., a move that includes pulling out of the Francis Crick Institute and the London BioScience Innovation Center, which will leave 125 employees jobless. The pharma giant is also pulling the plug on a roughly $1.3 billion construction project that was expected to open 120 posts for researchers and technicians. A company spokesperson said the moves reflect “the challenges of the U.K. not making meaningful progress towards addressing the lack of investment in the life science industry.” Successive U.K. governments, the spokesperson continued, have also demonstrated an “overall undervaluation of innovative medicines and vaccines.”
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
September 3, 2025
Novartis - East
Layoffs
East Hanover, NJ
50,001+ employees
Novartis is parting ways with 58 employees from its U.S. headquarters in East Hanover, New Jersey. The headcount reduction comes as the company is “evaluating opportunities to enhance processes, increase efficiencies, and ensure we are investing our time and resources into the areas where we can have the greatest impact,” the spokesperson added.
Disease Area: Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
August 29, 2025
Exelixis
Facility Closure, Layoffs
Alameda, CA
1,001-5,000 employees
Exelixis will shutter its facility in King of Prussia, Pennsylvania, and is laying off 130 employees companywide as the cancer specialist rightsizes its operations after a pandemic-era boom in hiring. While a company statement provided to BioSpace did not give an exact breakdown of where affected staffers are located, 71 people at the biotech’s Alameda, California, headquarters are being let go effective Oct. 27. In addition, Fierce Biotech has reported that 33 remote employees who report to California-based managers are being cut. According to the statement, Exelixis hired a significant number of employees—including many remote workers—during the pandemic and post-pandemic period to meet business needs. The biotech is now reorganizing its structure to focus largely on its Alameda operations. It expects to reopen many of the affected positions as new roles at its headquarters.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
August 28, 2025
Pfizer
Layoffs
New York, NY
50,001+ employees
A hundred jobs at Pfizer’s Bothell, Washington site are on the chopping block amid the Big Pharma’s aggressive cost-cutting measures. In a statement to Fierce Pharma on Tuesday, a Pfizer spokesperson said the retrenchment effort is part of the company’s push to improve “R&D productivity and efficiency with a sharpened focus on opportunities.” The pharma is also “simplifying the way it works through digital enablement and automation, which we believe will deliver the greatest impact for patients,” the spokesperson added.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
August 22, 2025
CERO THERAPEUTICS HOLDINGS, INC.
Negative Outlook
South San Francisco, California
1-50 employees
For example, the Medicare Drug Price Negotiation Program, administered by CMS as part of the Inflation Reduction Act of 2022, commonly referred to as the IRA, may apply to our products if they are selected for negotiation, which could materially reduce the amount of revenue we can generate from our products if they are approved.
Disease Area: Oncology
Drug Type: Small Molecule
August 19, 2025
Windtree Theraputics INC
Neutral Outlook
Warrington, Pennsylvania
1-50 employees
…recently enacted and future legislation, including but not limited to, the Inflation Reduction Act of 2022, regarding the healthcare system in the U.S. or the healthcare systems in foreign jurisdictions;
Disease Area: Cardiovascular, Oncology, Respitory
Drug Type: Small Molecule